Denial Of Xtandi March-In Rights Petition Appealed To HHS
The rejection of a request for the government to use so-called march-in rights to lower the price of the Astellas Pharma Inc. and Pfizer Inc. prostate cancer drug Xtandi by granting...To view the full article, register now.
Already a subscriber? Click here to view full article